Bacteria Bacterium Immune Response Protein 
Drug Discovery World
JULY 29, 2022
From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. But with hundreds of bacterial species populating our gastrointestinal tract, it’s a daunting task to pinpoint which molecules made by which bacteria affect which biological processes—and how they do so.
pharmaphorum
DECEMBER 4, 2020
This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JANUARY 20, 2021
While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.
pharmaphorum
JULY 14, 2021
Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.
pharmaphorum
MAY 31, 2022
Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. GSK said it is paying $2.1
Expert insights. Personalized for you.
52 
Let's personalize your content